A novel GABAergic dysfunction in human Dravet syndrome

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Dravet syndrome is a rare neurodevelopmental disorder characterized by severe seizures and cognitive impairment, often linked to SCN1A gene mutations affecting sodium channels.
• A potential GABAergic (γ-aminobutyric acid) system impairment is hypothesized to contribute to Dravet syndrome pathophysiology, but underlying mechanisms remain unclear due to limited brain tissue availability.

Purpose of the Study:

• To investigate the physiological mechanisms of GABAergic dysfunction in Dravet syndrome using human cortical brain tissue.
• To explore the potential of GABAergic therapies and compounds like cannabidiol for Dravet syndrome.

Main Methods:

• Human cortical brain tissue from Dravet syndrome patients, tuberous sclerosis complex patients, and controls was used.
• Cell membranes were transplanted into Xenopus oocytes to study human GABA_A receptors and currents using voltage-clamp techniques.
• Quantitative real-time PCR, immunohistochemistry, and double-labeling were employed to analyze receptor expression and chloride transporter levels.

Main Results:

• Reduced GABA sensitivity and a shift in GABA reversal potential were observed in Dravet syndrome, associated with altered GABA_A receptor subunit composition (increased α4/α1 ratio) and chloride transporter expression (NKCC1/KCC2).
• Low doses of cannabidiol significantly increased GABA_A currents in both Dravet syndrome and tuberous sclerosis complex tissues, comparable to flunitrazepam.
• These effects on GABA_A currents persisted even in the absence of the gamma subunit.

Conclusions:

• GABAergic system dysfunction, alongside defective sodium channels, contributes to reduced neural inhibition in Dravet syndrome.
• GABA_A receptors represent a potential therapeutic target for Dravet syndrome, with cannabidiol showing promise in modulating GABAergic neurotransmission.